Normal
Discovery Pipeline

In addition to its five lead compound drug candidates, ImmuPharma has a proprietary discovery process for generating more novel compounds for developing internally or licensing to others.

The key source of ImmuPharma’s compounds comes through a successful R&D collaboration with Centre National de la Recherche Scientifique (CNRS). This could potentially further enhance ImmuPharma’s pipeline with additional assets.

The company currently has two sources of patented new molecules from which it expects to generate one new lead compound a year.

Discovery pipeline

  • Our library of heterocyclic urea molecules has a high proportion of drug-like molecules, making a promising base to discover new compounds using drugs modelling peptide delivery.
  • Our innovative peptide to drug converting technology (PDCT) gives us the capability to turn small peptides into potential drug products with lower than usual development risks.